A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).
Wednesday, June 19, 2024
Dr. Minal Barve
Click the above link to view the abstract.
![ASCO 2024 Poster for Trial 22-26](https://marycrowley.org/wp-content/uploads/2024/06/Poster-12.jpg)
ASCO 2024 Poster for Trial 22-26